Yohann Loriot, MD, PhD, is currently a Professor of Medicine at Paris-Saclay University and Deputy Chair of the Department of Early Drug Development at Gustave Roussy, Villejuif, France. He is a medical oncologist at Gustave Roussy, specializing in the care of patients with genitourinary cancers (urothelial, prostate, and testicular cancers). He is a past recipient of the Young Oncologist Award from the American Society of Clinical Oncology. His major research focuses on drug development, particularly in connection with biomarker discovery, targeted therapies, and immunotherapies. His team, located at the INSERM U981 laboratory, aims to identify mechanisms of action and resistance to innovative therapies, working in the fields of basic science, bioinformatics, and clinical research. He also leads phase I-III trials testing new drugs in urothelial and prostate cancers. Pr. Loriot is currently a member of the steering committees for multiple international clinical trials from phase I to phase III, which have led to several drug approvals (erdafitinib, enzalutamide, abiraterone, atezolizumab, sacituzumab, enfortumab). He has published more than 300 peer-reviewed papers, including papers in New England Journal of Medicine, Lancet Oncology, JCO and Cancer Discovery, as first or senior author. Pr. Loriot is a member of several scientific committees for international academic groups, including the Genitourinary Committee of EORTC (Chair), UNICANCER (member of the steering committee), and the European Society of Medical Oncology (ESMO) non prostate GU Group (faculty). He is also a member of the editorial boards of Annals of Oncology and European Journal of Cancer.